C12N 2320/31
Combination therapy
C12N2320/31 (Combination therapy) appears on 960 US grants and 2,015 published applications in this corpus.
Search patents in C12N- Granted patents
- 960
- Published applications
- 2,015
- Assignees
- 807
- Inventors
- 3,360
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 9 |
| 2004 | 0 | 11 |
| 2005 | 0 | 13 |
| 2006 | 1 | 19 |
| 2007 | 3 | 11 |
| 2008 | 0 | 18 |
| 2009 | 10 | 37 |
| 2010 | 13 | 51 |
| 2011 | 19 | 47 |
| 2012 | 28 | 52 |
| 2013 | 27 | 68 |
| 2014 | 40 | 75 |
| 2015 | 54 | 100 |
| 2016 | 57 | 161 |
| 2017 | 79 | 144 |
| 2018 | 83 | 119 |
| 2019 | 96 | 115 |
| 2020 | 65 | 129 |
| 2021 | 71 | 174 |
| 2022 | 79 | 207 |
| 2023 | 61 | 146 |
| 2024 | 66 | 137 |
| 2025 | 50 | 96 |
| 2026 | 55 | 76 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for reprogramming age-restricted non-neuronal cells29 Sep 2026US 12,747,438 B2The Regents of the University of California
- Compositions and methods for treatment of hepatitis D virus infection15 Sep 2026US 12,735,699 B2GlaxoSmithKline Intellectual Property (No. 3) Limited
- Anticancer adjuvant and pharmaceutical composition for treating anticancer-agent-resistant cancer, and kit comprising same15 Sep 2026US 12,735,704 B2Dong-A University Research Foundation for Industry-Academy Cooperation
- Sex-linked RNAi insecticide materials and methods25 Aug 2026US 12,714,111 B2Indiana University Research and Technology Corporation
- Nanometric pharmaceutical composition in the form of liposomes or nanoemulsion containing specific sequences of interference RNA18 Aug 2026US 12,708,671 B2
- Adenine base editors with reduced off-target effects8 Oct 2026US 2026/0308561 A1President and Fellows of Harvard College
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use1 Oct 2026US 2026/0297591 A1Arrowhead Pharmaceuticals, Inc.
- Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases24 Sep 2026US 2026/0286363 A1Wylder Nation Foundation
Most cited
By later US patents
- Oligomers139US 8,324,371 B2Royal Holloway and Bedford New College, University of London · 2012
- Oligomers125US 8,084,601 B2Royal Holloway and Bedford New College Royal Holloway, University of London · 2011
- RNA interference in respiratory epitheial cells121US 7,297,786 B2University of Iowa Research Foundation · 2007
- Therapeutic uses of inhibitors of RTP801L103US 7,626,015 B2Quark Pharmaceuticals, Inc. · 2009
- Methods for increasing efficacy of lipid formulated siRNA103US 9,051,567 B2Tekmira Pharmaceuticals Corporation · 2015